Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343187 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00343187: Clinical Trial Phase 2 study, sponsored by Allergan.
NCT00343187 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00343187, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of ACZONE in subjects treated with the HER1/EGFR inhibitor Tarceva (erlotinib) who develop a rash on the face
Interventions
- DRUG Vehicle Control
- DRUG ACZONE (dapsone) Gel, 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Why NCT00343187 stopped before completion
NCT00343187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle Control is the first listed.
NCT00343187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00343187 about?
NCT00343187 is a clinical study titled "A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash". The purpose of this study is to evaluate the safety and preliminary efficacy of ACZONE in subjects treated with the HER1/EGFR inhibitor Tarceva (erlotinib) who develop a rash on the face
What is the current status of trial NCT00343187?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2006-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00343187?
The interventions under investigation include: Vehicle Control (DRUG), ACZONE (dapsone) Gel, 5% (DRUG).
Who is sponsoring clinical trial NCT00343187?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00343187's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia